<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643823</url>
  </required_header>
  <id_info>
    <org_study_id>HYK-Rheumatoid Arthritis</org_study_id>
    <nct_id>NCT02643823</nct_id>
  </id_info>
  <brief_title>Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis</brief_title>
  <official_title>Safety and Efficacy Study of Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Hornetcorn Bio-technology Company, LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Futian People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Hornetcorn Bio-technology Company, LTD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of human umbilical cord
      mesenchymal stem cell(hUC-MSC) for Rheumatoid Arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into
      chondrocyte and osteocyte, which have been confirmed in in vivo and in vitro experiments.
      There have been few clinical reports describing umbilical cord mesenchymal stem cells for
      treatment of Rheumatoid Arthritis.

      To investigate the effects of hUC-MSC treatment for Rheumatoid Arthritis, 20 patients with
      Rheumatoid Arthritis will be enrolled and receive 4 times of hUC-MSC transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>According to National Cancer Institute Common Terminology Criteria for Adverse Events（NCI-CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RA Serology</measure>
    <time_frame>1, 3 ,6 and 12 months</time_frame>
    <description>Rheumatoid Factor, C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score (DAS 28) Index</measure>
    <time_frame>1, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>hUC-MSC + DMARDs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated in combination with hUC-MSC and DMARDs with a 12 months follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMARDs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) with a 12 months follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hUC-MSC + DMARDs</intervention_name>
    <description>Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.</description>
    <arm_group_label>hUC-MSC + DMARDs</arm_group_label>
    <other_name>Human Umbilical Cord-Mesenchymal Stem Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMARDs</intervention_name>
    <description>Patients will be treated by conventional drugs (DMARDs) for alleviating disease.</description>
    <arm_group_label>DMARDs</arm_group_label>
    <other_name>NSAIDs</other_name>
    <other_name>Methotrexate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-80 Rheumatoid Arthritis patient;

          -  Patients must consent in writing to participate in the study by signing and dating an
             informed consent document;

          -  Patients must have a diagnosis of Rheumatoid Arthritis according to the 2010 ACR/EULAR
             criteria for at least 12 weeks duration;

          -  Stage I and II according to X-ray.

        Exclusion Criteria:

          -  History of neurological disease, head injury or psychiatric disorder;

          -  Pregnant women;

          -  Impaired liver function, abnormal blood coagulation, AIDS, HIV, combine other tumor or
             special condition;

          -  Progressive apoplexy;

          -  With malignant tumors;

          -  Patients who had participated in other clinical trials within three months prior to
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhong Z Ye, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Futian People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei J Zhong</last_name>
    <phone>+86 0755-83980805</phone>
    <email>ZhongJW@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Fourth People's Hospital of Shenzhen</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao J, Professor</last_name>
      <phone>0755-83981333</phone>
      <email>HaoJ@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Umbilical Cord Mesenchymal Stem Cell</keyword>
  <keyword>Mesenchymal Stem Cell</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

